Synergy Pharmaceuticals, Inc. (NASDAQ:SGYP) – Equities research analysts at Cantor Fitzgerald decreased their FY2017 EPS estimates for shares of Synergy Pharmaceuticals in a research note issued on Sunday. Cantor Fitzgerald analyst W. Tanner now anticipates that the biopharmaceutical company will earn ($1.20) per share for the year, down from their previous forecast of ($1.09). Cantor Fitzgerald has a “Overweight” rating and a $11.00 price target on the stock. Cantor Fitzgerald also issued estimates for Synergy Pharmaceuticals’ FY2018 earnings at ($0.71) EPS.

SGYP has been the subject of several other research reports. HC Wainwright reaffirmed a “buy” rating and set a $18.00 target price on shares of Synergy Pharmaceuticals in a research note on Friday, May 19th. BTIG Research reaffirmed a “buy” rating and set a $11.00 target price on shares of Synergy Pharmaceuticals in a research note on Friday, September 8th. Zacks Investment Research cut Synergy Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Tuesday, July 18th. BidaskClub raised Synergy Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Friday, June 23rd. Finally, Citigroup Inc. reaffirmed a “sell” rating and set a $3.70 target price on shares of Synergy Pharmaceuticals in a research note on Wednesday, June 28th. Three research analysts have rated the stock with a sell rating, one has issued a hold rating and nine have assigned a buy rating to the company. The company currently has a consensus rating of “Hold” and a consensus price target of $9.43.

ILLEGAL ACTIVITY NOTICE: “Synergy Pharmaceuticals, Inc. (SGYP) to Post FY2017 Earnings of ($1.20) Per Share, Cantor Fitzgerald Forecasts” was originally published by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are reading this piece of content on another domain, it was illegally copied and republished in violation of United States & international trademark and copyright law. The correct version of this piece of content can be read at https://www.thecerbatgem.com/2017/09/13/synergy-pharmaceuticals-inc-sgyp-to-post-fy2017-earnings-of-1-20-per-share-cantor-fitzgerald-forecasts.html.

Synergy Pharmaceuticals (NASDAQ SGYP) opened at 2.84 on Wednesday. Synergy Pharmaceuticals has a 12-month low of $2.63 and a 12-month high of $7.15. The stock’s 50 day moving average price is $3.31 and its 200 day moving average price is $4.14. The company’s market cap is $638.87 million.

Synergy Pharmaceuticals (NASDAQ:SGYP) last released its quarterly earnings data on Wednesday, August 9th. The biopharmaceutical company reported ($0.33) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.25) by ($0.08). The firm had revenue of $2.31 million during the quarter, compared to analyst estimates of $1.98 million. During the same quarter in the previous year, the business earned ($0.23) EPS.

In other Synergy Pharmaceuticals news, major shareholder Paulson & Co. Inc. sold 26,287 shares of the stock in a transaction that occurred on Monday, August 7th. The stock was sold at an average price of $3.77, for a total value of $99,101.99. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. 3.80% of the stock is currently owned by corporate insiders.

Several hedge funds have recently bought and sold shares of the company. Vanguard Group Inc. lifted its holdings in shares of Synergy Pharmaceuticals by 10.4% in the second quarter. Vanguard Group Inc. now owns 17,422,326 shares of the biopharmaceutical company’s stock valued at $77,530,000 after purchasing an additional 1,636,563 shares in the last quarter. State Street Corp lifted its holdings in shares of Synergy Pharmaceuticals by 2.4% in the second quarter. State Street Corp now owns 12,933,104 shares of the biopharmaceutical company’s stock valued at $57,552,000 after purchasing an additional 306,989 shares in the last quarter. Northern Trust Corp lifted its holdings in shares of Synergy Pharmaceuticals by 15.3% in the second quarter. Northern Trust Corp now owns 2,804,768 shares of the biopharmaceutical company’s stock valued at $12,481,000 after purchasing an additional 372,683 shares in the last quarter. TimesSquare Capital Management LLC lifted its holdings in shares of Synergy Pharmaceuticals by 2.7% in the second quarter. TimesSquare Capital Management LLC now owns 2,568,500 shares of the biopharmaceutical company’s stock valued at $11,430,000 after purchasing an additional 68,500 shares in the last quarter. Finally, Kingdon Capital Management L.L.C. lifted its holdings in shares of Synergy Pharmaceuticals by 42.7% in the first quarter. Kingdon Capital Management L.L.C. now owns 2,237,701 shares of the biopharmaceutical company’s stock valued at $10,428,000 after purchasing an additional 669,214 shares in the last quarter. Institutional investors own 71.48% of the company’s stock.

Synergy Pharmaceuticals Company Profile

Synergy Pharmaceuticals Inc is a biopharmaceutical company focused on the development and commercialization of gastrointestinal (GI) therapies. The Company’s product candidates include TRULANCE (plecanatide) and dolcanatide. The Company is engaged in the discovery, research and development efforts around analogs of uroguanylin for the treatment of GI diseases and disorders.

Earnings History and Estimates for Synergy Pharmaceuticals (NASDAQ:SGYP)

Receive News & Stock Ratings for Synergy Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Synergy Pharmaceuticals Inc. and related stocks with our FREE daily email newsletter.